



Chemical Probe BAY-299

BRPF2 / TAF1(2) probe

Léa Bouché and Bernard Haendler


April 6th, 2016

Hit cluster identification

Virtual screening and HTS










Background

BRPF and TAF1 bromodomain proteins











- BRPF proteins interact with DNA and histones, and form complexes with HATs
- TAF1/TAF1L proteins are very similar and part of transcription factor IID complex which controls transcription initiation


Characterization of BAY-299 BRPF2, TAF1 and TAF1L inhibition
















- BAY-299 is a potent BRPF2, TAF1(2) and TAF1L(2) bromodomain inhibitor
- Activity was shown using different biochemical assays


Characterization of BAY-299 BRPF2 and TAF1 binding











BAY-299 binds to BRPF2 and TAF1(2) with high affinity

Investigation of binding mode (X-ray) BRPF2 complex with close congener BAY-078






Selectivity Handle


- H-bond between cmpd C=O & protein backbone (SER⁶⁰)
- Similar H-bond in BRPF1 not possible (BRPF1 has a proline at this position) → selectivity

Induced Fit:


Glutamine (GLN⁵⁷) sidechain conformation "flips" to interact with tricyclic ring system




BAY-078



- Core
- Methyl induces favorable twist in cmpd required for binding
- H-bond between headgroup and Asparagine (ASN¹¹⁰)



- 4 key interactions seen for BAY-078, likely to be similar for BAY-299
- X-ray with BAY-299 ongoing





Selectivity over other bromodomains

AlphaScreen and TR-FRET









$$IC_{50}$$
 (BRPF2) = 63 nM* IC_{50} (TAF1(2)) = 14 nM*

$$IC_{50}$$
 (BRPF1) = 2280 nM (36 fold)
 IC_{50} (BRPF3) = 2450 nM (39 fold)

$$IC_{50}$$
 (BRD9) = 2125 nM (34 fold)*
 IC_{50} (ATAD2) = >20000 nM (>300 fold)*

$$IC_{50}$$
 (CREBBPA) = 1710 nM (27 fold)
 IC_{50} (CECR2) = 4660 nM (74 fold)
 IC_{50} (BRD4) = >20000 nM (>300 fold)*

BAY-299 is selective over other bromodomains

- >30-fold selective over the other members of the BRPF family
- >30-fold selective over close neighbors BRD9 and ATAD2
- >300-fold selective over BRD4

^{*} determined by TR-FRET


Selectivity over other bromodomains

Thermal Shift Assay and BromoScan





	TSA Bromopanel @ SGC (@ 10 µM)						
1	protein	ΔTm	stdev	26	FALZ	2,8	1,2
2	ASH1L	1,5	0,5	27	GCN5L2	1,9	0,8
3	ATAD2	2,0	0,5	28	ATAD2B	1,5	0,5
4	BAZ1A	0,8	0,5	29	SP140L	2,1	1,4
5	BAZ1B	0,6	0,5	30	MLL	0,7	0,3
6	BAZ2A	1,5	0,4	31	PB1(1)	1,1	0,3
7	BAZ2B	1,6	0,4	32	PB1(2)	0,1	0,1
8	BRPF2	8,5	0,1	33	PB1(3)	0,5	0,3
9	BRD2(1)	3,2	0,3	34	PB1(4)	1,2	0,3
10	BRD2(2)	1,3	0,3	35	PB1(5)	1,0	0,1
11	BRD3(1)	3,1	1,0	36	PB1(6)	0,8	0,2
12	BRD3(2)	1,7	0,6	37	PCAF	1,5	0,3
13	BRD4(1)	2,4	0,7	38	PHIP(2)	1,1	0,8
14	BRD4(2)	3,4	0,8	39	SMARCA2	0,3	0,1
15	BRD7	2,8	0,3	40	SMARCA4	0,9	0,1
16	BRD9	1,6	0,1	41	SP140	1,7	1,0
17	BRDT(1)	0,9	0,3				
18	BRDT(2)	1,8	0,5	42	TAF1(2)	3,6	0,2
19	BRPF1A	0,8	0,3	43	TAF1(1)	1,4	0,3
20	BRPF1B	2,4	0,3	44	TAF1L(1)	1,4	0,3
21	BRPF3	3,4	0,5	45	TAF1L(2)	4,8	0,6
22	BRWD3(2)	1,4	0,5	46	TIF1-bromo	1,4	0,5
23	CECR2	3,2	0,4	47	TIF1-phd-bromo	0,6	0,3
24	CREBBP	4,6	0,2	48	TRIM28	0,6	0,7
25	EP300	4.8	0,4	49	WDR9(2)	0,7	0,5




- Selectivity of BAY-299 is confirmed in larger bromodomain panel
- Strongest thermal shift observed for BRPF2
- Additional activity seen for TAF1(2) and TAF1L(2)
- Binding seen for CREBBP not observed in AlphaScreen (previous slide) or ITC (K_D = 1.4 μM)

Characterization of BAY-299

Cellular potency: NanoBRET results





	BAY-299 IC ₅₀ (nM)
BRPF2 BD/H3.3	825
BRPF2 BD/H4	575
TAF1 BD2/H3.3	1400
TAF1 BD2/H4	970
BRPF1 BD/H4	>10000
BRD4 FL/H4	>10000

- BAY-299 shows strong cellular activity
 - Inhibition of BRPF2 BD/H3.3 and H4 interaction
 - Inhibition of TAF1 BD2/H3.3 and H4 interaction
 - Disruption of chromatin binding
- No inhibition of BRPF1 BD/H4 or BRD4 FL/H4 interaction

BRPF2 / TAF1(2) probe BAY-299

Overview





HO N N N N N N N N N N N N N N N N N N N
BAY-299

Lead-like profile				
MW _{corrected}	429.5 g/mol			
TPSA	81 Ų			
Measured logD (pH 7.5)	2.0			
Calculated logD (pH 7.5)	2.5			
Solubility	10 mg/L			
Stability in r/h plasma	Stable for at least 4 h at 37 °C			

-	Basic profile					
IC ₅₀ BRPF2 (TF	R-FRET / AlphaScreen)	67 / 63 nM				
IC ₅₀ TAF1(2) (T	R-FRET)	14 nM				
Selectivity	IC ₅₀ BRPF1 (TR-FRET / AlphaScreen)	3150 / 2280 nM				
	IC ₅₀ BRPF3 (AlphaScreen)	2450 nM				
	IC ₅₀ BRD4 (TR-FRET)	>20000 nM				
IC ₅₀ (BRPF2 BI	575 nM					
IC ₅₀ (TAF1 BD2	970 nM					
GI ₅₀ Proliferation	900 - >10000 nM					
Selectivity Kina	>20000 nM					
Selectivity Lead	profiling screen (# = 68)	>5000 nM				

in vitro pharmacokinetic profile						
	CL _{int} [L/h/kg]		F _{max} [%]			
Hepatocytes	dog / rat	1.5 / 3.8		13 /	9.4	
Liver	mouse / rat	0.19 / 0.15		96 / 96		
Microsomes	dog / human	<0.001 / <0.001		100 / 100		
Caco2 permeability		P _{app} (A-B) [nm/s]	P	_{app} (B-A) [nm/s]	Ratio	
		163		191	1.2	

Characterization of probe BAY-299


Atropisomerism





Methyl group induces axial chirality

$$R = HO$$



• Similar experimental profile, e.g. (see full profile in the backup)

	TAF1 IC ₅₀ ,HTRF [nM]	BRPF2 IC ₅₀ ,HTRF [nM]	BRPF1 IC ₅₀ ,HTRF [nM]
Atrop 1	17	62	5860
Atrop 2	11	74	5490

- Calculated barrier height classifies BAY-299 as class 2 atropisomers (*J. med. Chem.* 2011, *54*, 7005-7022): General scientific recommendation to develop as a mix (racemate)
- Stirring experiments:
- at 37 °C in DMSO and CH₃CN showed begin of racemization after 1 week;
- at 80 °C in DMSO showed 30% racemization after 2 days.


→ Decision for racemate (BAY-299)

Negative control of BAY-299

Proposed candidate







Lead-like properties				
MW _{corrected}	401.4 g/mol			
TPSA	90 Ų			
Measured logD (pH 7.5)	1.7			
Calculated logD (pH 7.5)	1.6			
Solubility	ongoing			

Basic profile						
IC ₅₀ BRPF2 (TI	R-FRET, AlphaScreen)	>20000 nM				
IC ₅₀ TAF1(2) (T	R-FRET)	2880 nM				
Selectivity	Selectivity IC ₅₀ BRPF1 (TR-FRET, AlphaScreen)					
	IC ₅₀ BRD4 (TR-FRET)	>20000 nM				
IC ₅₀ (BRPF2 B	IC ₅₀ (BRPF2 BD/H4) Cellular assay					
IC ₅₀ (TAF1 BD2	>10000 nM					
GI ₅₀ Proliferati	>10000 nM					
Selectivity Kina	ses (# = 14)	>15000 nM				


in vitro pharmacokinetic profile						
CL _{int} [L/h/kg] F _{max} [%]						
Hepatocytes	rat	3.7		1	3	
Liver Microsomes	human	0.0042	0.0042		100	
Caco2 permeability		P _{app} (A-B) [nm/s]	P _a	_{app} (B-A) [nm/s]	Ratio	
	25 18		189	7.4		

BRPF2 / TAF1 probe BAY-299

Summary







- First potent and cell permeable BRPF2 inhibitor with high selectivity towards BRPF1 (34-fold) and BRPF3 (39-fold)
- BAY-299 shows no activity on BRD4
- Cellular activity for BRPF2 confirmed in NanoBRET
- Additional potent TAF1(2) inhibition, confirmed in NanoBRET
- Bromodomain selectivity tested in TR-FRET, BromoScan,
 AlphaScreen and TSA
- Selectivity vs. other targets determined in kinase panel (inhouse) and Lead Profiling Screen (Eurofins Panlabs)

BAY-299 is proposed as a dual BRPF2 and TAF1(2) probe

BRPF2 / TAF1 probe BAY-299

Acknowledgements







Amaury Ernesto Fernández-Montalván Antonius ter Laak Clara Christ **Detlef Stoeckigt** Oliver Schenk Simon Holton Stephan Siegel Ursula Egner

Andrea Haegebarth Ingo Hartung Marcus Bauser

Cora Mund Marion Hitchcock

Anke Mueller-Fahrnow



Julia Meier John Porter Kilian Huber Oleg Fedorov Peter Brown Susanne Müller-Knapp **Tony Tumber**





Thank you!

Literature known chemical probes BRPF inhibitors





BRPF1B inhibitor

 IC_{50} (BRPF1) = 42 nM IC_{50} (BRPF2) = 869 nM IC_{50} (BRD4) = 8340 nM

(Med. Chem. Lett., **2014**, *5*, 1190-1195)

BRPF1,2,3 inhibitor

OF-1

 IC_{50} (BRPF1) = 85 nM IC_{50} (BRPF2) = 892 nM IC_{50} (BRD4) = 9200 nM

(*J. Med.Chem.*, **2016**, *59*, 1642-1647)

BRPF1,2,3 inhibitor

NI-57

 IC_{50} (BRPF1) = 25 nM IC_{50} (BRPF2) = 137 nM IC_{50} (BRD4) = 6620 nM

(WO 2016/034512 A1)

BRPF1B inhibitor

 IC_{50} (BRPF1) = 30 nM IC_{50} (BRPF2) = 1270 nM IC_{50} (BRD4) = 9080 nM

(Med. Chem. Lett., **2014**, *5*, 1190-1195)


Chemical probes

Selectivity over other bromodomains

Full BromoScan data for BAY-299







Similar selectivity profile as observed in SGC's TSA panel

Characterization of probe BAY-299 in vitro DMPK of BAY-299





Honotopytop		CL _{in}	CL _{int} [L/h/kg]		F _{max} [%]		
Hepatocytes	rat/dog	3.	3.8 / 1.5		9.4 / 13		
Liver	mouse/rat	0.1	0.19 / 0.15		0.19 / 0.15 96 / 96		6
Microsomes	dog/human	<0.00	1 / <0.001		100 / 10	00	
Caco2 permeability		P _{app} (A-B) [nm/s]		P _{app} ([nn		Ratio	
		163		19	91	1.2	
		1A2	2C8	2C9	2D6	3A4	
CYP inhibi	CYP inhibition [µM]		>20	>20	>20	>20	
CYP ind	PXR flag green; NOEL(1A2) > 10000 μg/L, NOEL(3A4) = 1111 μg/L (hint on CAR-mediated induction)			(no hint on TDI)			

- Metabolic stability of BAY-299 is high in liver microsomes across species, but low in hepatocytes of rat and dog
- BAY-299 cell permeability is high with no hint on active transport
- CYP inh >20 µM and no hint on time-dependent inhibition

Characterization of probe BAY-299

Comparison of the corresponding atropisomers



	Basic profile	BAY-299	Atrop 1	Atrop 2
IC ₅₀ TAF1 (T	(TR-FRET) 14 nM		17 nM	11 nM
IC ₅₀ BRPF2	(TR-FRET)	67 nM	62 nM	74 nM
Selectivity	IC ₅₀ BRPF1 (TR-FRET)	3150 nM	5860 nM	5490 nM
	IC ₅₀ BRD4 (TR-FRET)	>20000 nM	>20000 nM	>20000 nM
	IC ₅₀ BRPF3 (AlphaScreen)	2450 nM	2160 nM	4170 nM
	IC ₅₀ BRD9 (TR-FRET)	>4250 nM	5040 nM	2190 nM
K _D (BRPF2)	ITC	45 nM	36 nM	37 nM
IC ₅₀ (BRPF2) Cellular mechanistic assay		500 nM	354 nM	565 nM
CaCo2 Papp(A-B) / Papp(B-A) [nm/s] / ratio		163 / 191 / 1.2	181 / 183 / 1.0	151 / 206 / 1.4

Similar profiles for BAY-299 (racemate) and individual atropisomers